{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:54:58Z","timestamp":1785304498498,"version":"3.55.0"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["1 R01 AR060823"],"award-info":[{"award-number":["1 R01 AR060823"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Matrix Biology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.matbio.2018.03.010","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T17:38:00Z","timestamp":1520876280000},"page":"294-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Osteogenesis imperfecta and therapeutics"],"prefix":"10.1016","volume":"71-72","author":[{"given":"Roy","family":"Morello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.matbio.2018.03.010_bb0005","series-title":"Tabulae ad illustrandam embryogenesin hominis et mammalium, naturalem tam abnormem","author":"Vrolik","year":"1849"},{"key":"10.1016\/j.matbio.2018.03.010_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0940-9602(02)80023-1","article-title":"Aspects of the history of osteogenesis imperfecta (Vrolik's syndrome)","volume":"184","author":"Baljet","year":"2002","journal-title":"Ann. Anat."},{"key":"10.1016\/j.matbio.2018.03.010_bb0015","series-title":"Osteogenesis Imperfecta: A Study of Clinical Features and Heredity Based on 55 Danish Families Comprising 180 Affected Members","author":"Seedorf","year":"1949"},{"key":"10.1016\/j.matbio.2018.03.010_bb0020","series-title":"Clinical, Genetic, Epidemiological and Socio-medical Aspects","article-title":"Osteogenesis imperfecta in Sweden","author":"Smars","year":"1961"},{"key":"10.1016\/j.matbio.2018.03.010_bb0025","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(78)90763-8","article-title":"Classification of osteogenesis imperfect","volume":"1","author":"Sillence","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.matbio.2018.03.010_bb0030","first-page":"113","article-title":"Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity","volume":"15","author":"Sillence","year":"1979","journal-title":"Birth Defects Orig. Artic. Ser."},{"key":"10.1016\/j.matbio.2018.03.010_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0040","series-title":"The Chemistry and Biology of Collagen","year":"1979"},{"key":"10.1016\/j.matbio.2018.03.010_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM197907053010104","article-title":"The biosynthesis of collagen and its disorders (first of two parts)","volume":"301","author":"Prockop","year":"1979","journal-title":"New Engl J Med"},{"key":"10.1016\/j.matbio.2018.03.010_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM197907123010204","article-title":"The biosynthesis of collagen and its disorders (second of two parts)","volume":"301","author":"Prockop","year":"1979","journal-title":"New Engl J Med"},{"key":"10.1016\/j.matbio.2018.03.010_bb0055","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1073\/pnas.68.6.1138","article-title":"Evidence for procollagen, a biosynthetic precursors of collagen","volume":"68","author":"Bellamy","year":"1971","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.matbio.2018.03.010_bb0060","first-page":"501","article-title":"Osteogenesis imperfecta congenita: evidence for a generalized molecular disorder of collagen","volume":"36","author":"Trelstad","year":"1977","journal-title":"Lab. Investig."},{"key":"10.1016\/j.matbio.2018.03.010_bb0065","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1073\/pnas.78.8.5142","article-title":"Reduced secretion of structurally abnormal type I procollagen in a form of osteogenesis imperfecta","volume":"78","author":"Barsh","year":"1981","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.matbio.2018.03.010_bb0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/304078a0","article-title":"Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta","volume":"304","author":"Chu","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2018.03.010_bb0075","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1016\/S0021-9258(18)90635-6","article-title":"Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation","volume":"259","author":"Pihlajaniemi","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0080","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0021-9258(20)71150-6","article-title":"Multiexon deletion in an osteogenesis imperfecta variant with increased type III collagen mRNA","volume":"260","author":"Chu","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0085","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1073\/pnas.82.9.2870","article-title":"Intron-mediated recombination may cause a deletion in an alpha 1 type I collagen chain in a lethal form of osteogenesis imperfecta","volume":"82","author":"Barsh","year":"1985","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.matbio.2018.03.010_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0174-173X(85)80020-0","article-title":"Altered helical structure of a homotrimer of alpha 1(I)chains synthesized by fibroblasts from a variant of osteogenesis imperfecta","volume":"5","author":"Deak","year":"1985","journal-title":"Coll. Relat. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0095","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","article-title":"Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect","volume":"17","author":"Glorieux","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","article-title":"Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease","volume":"31","author":"Ward","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11914-007-0023-z","article-title":"Osteogenesis imperfecta: epidemiology and pathophysiology","volume":"5","author":"Martin","year":"2007","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.matbio.2018.03.010_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/humu.20429","article-title":"Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans","volume":"28","author":"Marini","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.matbio.2018.03.010_bb0120","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.matbio.2018.03.010_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.matbio.2018.03.010_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/JMDH.S113483","article-title":"Managing the patient with osteogenesis imperfecta: a multidisciplinary approach","volume":"10","author":"Marr","year":"2017","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.matbio.2018.03.010_bb0135","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/jbmr.2895","article-title":"Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study","volume":"31","author":"Folkestad","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0140","series-title":"Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease","first-page":"125","article-title":"Haploinsufficiency for mutations in type I collagen genes: mechanisms and clinical effects","author":"Byers","year":"2013"},{"key":"10.1016\/j.matbio.2018.03.010_bb0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0150","series-title":"Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease","first-page":"115","article-title":"Structural consequences of glycine missense mutations in osteogenesis imperfecta","author":"Brodsky","year":"2013"},{"key":"10.1016\/j.matbio.2018.03.010_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1242\/dmm.001966","article-title":"The first transgenic mice: an interview with Mario Capecchi. Interview by Kristin Kain","volume":"1","author":"Capecchi","year":"2008","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.matbio.2018.03.010_bb0160","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00198-013-2290-0","article-title":"Next-generation sequencing for disorders of low and high bone mineral density","volume":"24","author":"Sule","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajmg.a.30231","article-title":"Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2","volume":"131","author":"Ha-Vinh","year":"2004","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.matbio.2018.03.010_bb0175","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.matbio.2018.03.010_bb0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","article-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta","volume":"39","author":"Cabral","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJMoa0907705","article-title":"Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding","volume":"362","author":"Barnes","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.matbio.2018.03.010_bb0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"van Dijk","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0195","doi-asserted-by":"crossref","first-page":"17641","DOI":"10.1074\/jbc.M109.007070","article-title":"Biochemical characterization of the prolyl 3-hydroxylase 1.cartilage-associated protein.cyclophilin B complex","volume":"284","author":"Ishikawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0205","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ajhg.2010.02.022","article-title":"Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta","volume":"86","author":"Alanay","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0210","first-page":"582","article-title":"A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta","volume":"34","author":"Volodarsky","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.matbio.2018.03.010_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006156","article-title":"Absence of the ER cation channel TMEM38B\/TRIC-B disrupts intracellular calcium homeostasis and dysregulates collagen synthesis in recessive osteogenesis imperfecta","volume":"12","author":"Cabral","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0220","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1750-1172-8-154","article-title":"Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans","volume":"8","author":"Symoens","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.matbio.2018.03.010_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11920","article-title":"MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta","volume":"7","author":"Lindert","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.matbio.2018.03.010_bb0230","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.21647","article-title":"Identification of a mutation causing deficient BMP1\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta","volume":"33","author":"Martinez-Glez","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.matbio.2018.03.010_bb0235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ajhg.2015.04.021","article-title":"Recessive osteogenesis imperfecta caused by missense mutations in SPARC","volume":"96","author":"Mendoza-Londono","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.matbio.2016.02.001","article-title":"SPARC\/osteonectin in mineralized tissue","volume":"52\u201354","author":"Rosset","year":"2016","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","article-title":"Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta","volume":"88","author":"Becker","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0250","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/jbmr.487","article-title":"Mutations in SERPINF1 cause osteogenesis imperfecta type VI","volume":"12","author":"Homan","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0255","first-page":"723","article-title":"Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor causes progressively deforming osteogenesis imperfecta with normal type I collagen","volume":"3","author":"Venturi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0260","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A mutation in the 5\u2032-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus","volume":"91","author":"Semler","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0265","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5\u2032-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0270","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/jbmr.2173","article-title":"A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor","volume":"29","author":"Farber","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0280","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1086\/497706","article-title":"Clinical and molecular findings in osteoporosis-pseudoglioma syndrome","volume":"77","author":"Ai","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0285","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1215458","article-title":"WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta","volume":"368","author":"Laine","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jmedgenet-2013-101567","article-title":"Mutations in WNT1 are a cause of osteogenesis imperfecta","volume":"50","author":"Fahiminiya","year":"2013","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation","volume":"108","author":"Nakashima","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.matbio.2018.03.010_bb0300","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","article-title":"Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta","volume":"87","author":"Lapunzina","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0305","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/ajmg.a.37365","article-title":"Nosology and classification of genetic skeletal disorders: 2015 revision","volume":"167A","author":"Bonafe","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.matbio.2018.03.010_bb0310","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/ncomms2720","article-title":"Molecular mechanics of mineralized collagen fibrils in bone","volume":"4","author":"Nair","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.matbio.2018.03.010_bb0315","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jbmr.2835","article-title":"Bone material properties in osteogenesis imperfecta","volume":"31","author":"Bishop","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0320","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bonekey.2013.181","article-title":"Bone composition: relationship to bone fragility and antiosteoporotic drug effects","volume":"2","author":"Boskey","year":"2013","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.matbio.2018.03.010_bb0325","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.matbio.2015.02.003","article-title":"Proteoglycan form and function: a comprehensive nomenclature of proteoglycans","volume":"42","author":"Iozzo","year":"2015","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0330","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004978","article-title":"The collagen family","volume":"3","author":"Ricard-Blum","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0335","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1101\/gad.1276205","article-title":"Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone","volume":"19","author":"Murshed","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.matbio.2018.03.010_bb0340","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1399-0004.2011.01794.x","article-title":"Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix","volume":"82","author":"Valli","year":"2012","journal-title":"Clin. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0345","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0350","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0355","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1016\/S0021-9258(17)46833-5","article-title":"Mutations in the carboxyl-terminal propeptide of the pro alpha 1(I) chain of type I collagen result in defective chain association and produce lethal osteogenesis imperfecta","volume":"268","author":"Chessler","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0040007","article-title":"ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta","volume":"4","author":"Lisse","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0365","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1091\/mbc.e08-11-1092","article-title":"Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection","volume":"20","author":"Ishida","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.matbio.2018.03.010_bb0370","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2520","article-title":"Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations","volume":"10","author":"Bateman","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0375","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.tcb.2010.11.007","article-title":"Chaperoning osteogenesis: new protein-folding disease paradigms","volume":"21","author":"Makareeva","year":"2011","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0380","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddp481","article-title":"Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex","volume":"19","author":"Chang","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0385","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/jcb.20776","article-title":"Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development","volume":"98","author":"Zhang","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0390","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.matbio.2017.08.004","article-title":"Decorin and biglycan are necessary for maintaining collagen fibril structure, fiber realignment, and mechanical properties of mature tendons","volume":"64","author":"Robinson","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0395","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.matbio.2016.09.009","article-title":"Decorin interacting network: a comprehensive analysis of decorin-binding partners and their versatile functions","volume":"55","author":"Gubbiotti","year":"2016","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0400","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1074\/jbc.M110709200","article-title":"Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen","volume":"277","author":"Di Lullo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0405","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jbmr.5650100718","article-title":"Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta","volume":"10","author":"Fedarko","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0410","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/154405910708600402","article-title":"Is SPARC an evolutionarily conserved collagen chaperone?","volume":"86","author":"Martinek","year":"2007","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0415","first-page":"83","article-title":"Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions","volume":"88","author":"Melsen","year":"1980","journal-title":"Acta Pathol. Microbiol. Scand. A"},{"key":"10.1016\/j.matbio.2018.03.010_bb0420","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/jbmr.1901","article-title":"In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin","volume":"28","author":"Narisawa","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0425","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/BF02557842","article-title":"Role of proteoglycans in endochondral ossification: inhibition of calcification","volume":"37","author":"Dziewiatkowski","year":"1985","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0430","doi-asserted-by":"crossref","first-page":"33926","DOI":"10.1074\/jbc.R112.379602","article-title":"The biology of small leucine-rich proteoglycans in bone pathophysiology","volume":"287","author":"Nikitovic","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0435","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/386078a0","article-title":"Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein","volume":"386","author":"Luo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2018.03.010_bb0440","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1210\/en.2007-1205","article-title":"Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP","volume":"149","author":"Martin","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.matbio.2018.03.010_bb0445","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11926-003-0071-z","article-title":"Matrix vesicles and calcification","volume":"5","author":"Anderson","year":"2003","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.matbio.2018.03.010_bb0450","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002239900600","article-title":"The mineralization density of iliac crest bone from children with osteogenesis imperfecta","volume":"64","author":"Boyde","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0455","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00223-008-9113-x","article-title":"Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations","volume":"82","author":"Roschger","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0460","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bone.2009.10.037","article-title":"CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII","volume":"46","author":"Fratzl-Zelman","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0465","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/jbmr.3180","article-title":"Hypermineralization and high osteocyte lacunar density in osteogenesis imperfecta type V bone indicate exuberant primary bone formation","volume":"32","author":"Blouin","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0470","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2013.11.023","article-title":"Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations","volume":"60","author":"Fratzl-Zelman","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0475","series-title":"Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease","first-page":"31","article-title":"Mineralized tissue: histology, biology and biochemistry","author":"Boskey","year":"2013"},{"key":"10.1016\/j.matbio.2018.03.010_bb0480","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jbmr.3108","article-title":"Fkbp10 deletion in osteoblasts leads to qualitative defects in bone","volume":"32","author":"Lietman","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0485","doi-asserted-by":"crossref","first-page":"E325","DOI":"10.1210\/jc.2014-3082","article-title":"Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression","volume":"100","author":"Reich","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.matbio.2018.03.010_bb0490","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bone.2014.12.023","article-title":"Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone","volume":"73","author":"Fratzl-Zelman","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0495","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2012.03.007","article-title":"Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice","volume":"50","author":"Vanleene","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0500","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1242\/jcs.02830","article-title":"New insights into extracellular matrix assembly and reorganization from dynamic imaging of extracellular matrix proteins in living osteoblasts","volume":"119","author":"Sivakumar","year":"2006","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.matbio.2018.03.010_bb0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/JOE-10-0377","article-title":"Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor","volume":"209","author":"Kim","year":"2011","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0510","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2005-05-1822","article-title":"Developmental and functional significance of the CSF-1 proteoglycan chondroitin sulfate chain","volume":"107","author":"Nandi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2018.03.010_bb0515","series-title":"ASBMR","article-title":"The soluble form of RANKL contributes to cancellous bone remodeling in adult mice but is dispensable for ovariectomy-induced bone loss","author":"Xiong","year":"2017"},{"key":"10.1016\/j.matbio.2018.03.010_bb0520","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/10408360490460933","article-title":"Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation","volume":"41","author":"Hyytiainen","year":"2004","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"Pt 2","key":"10.1016\/j.matbio.2018.03.010_bb0525","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/bj3020527","article-title":"Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta","volume":"302","author":"Hildebrand","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.matbio.2018.03.010_bb0530","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng0303-331","article-title":"Fibrillin controls TGF-beta activation","volume":"33","author":"Kaartinen","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0535","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0540","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bbadis.2012.10.005","article-title":"Integrin-mediated regulation of TGFbeta in fibrosis","volume":"1832","author":"Henderson","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.matbio.2018.03.010_bb0545","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-4939-2966-5_18","article-title":"Role of TGF-beta signaling in coupling bone remodeling","volume":"1344","author":"Crane","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0550","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0555","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.matbio.2018.03.010_bb0560","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.71","article-title":"Integrins alpha2beta1 and alpha11beta1 regulate the survival of mesenchymal stem cells on collagen I","volume":"2","author":"Popov","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.matbio.2018.03.010_bb0565","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/hmg\/ddt611","article-title":"ITGB6 loss-of-function mutations cause autosomal recessive amelogenesis imperfecta","volume":"23","author":"Wang","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0570","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/jbmr.3190","article-title":"Integrin-linked kinase regulates bone formation by controlling cytoskeletal organization and modulating BMP and Wnt signaling in osteoprogenitors","volume":"32","author":"Dejaeger","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0575","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1203\/00006450-198303000-00007","article-title":"Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda","volume":"17","author":"Baron","year":"1983","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0580","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.matbio.2018.03.010_bb0585","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.etap.2016.01.015","article-title":"Bisphosphonates: pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development","volume":"42","author":"Soares","year":"2016","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0590","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0595","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.matbio.2018.03.010_bb0600","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0605","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-198801000-00017","article-title":"Is APD a promising drug in the treatment of severe osteogenesis imperfecta?","volume":"8","author":"Huaux","year":"1988","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.matbio.2018.03.010_bb0610","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"131","author":"Bembi","year":"1997","journal-title":"J. Pediatr."},{"key":"10.1016\/j.matbio.2018.03.010_bb0615","first-page":"261","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"157","author":"Fujiwara","year":"1998","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.matbio.2018.03.010_bb0620","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.matbio.2018.03.010_bb0625","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","article-title":"Experience with bisphosphonates in osteogenesis imperfecta","volume":"119","author":"Glorieux","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.matbio.2018.03.010_bb0630","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2018.03.010_bb0635","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.matbio.2018.03.010_bb0640","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.matbio.2018.03.010_bb0645","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11914-017-0401-0","article-title":"Long-term bisphosphonate therapy in osteogenesis imperfecta","volume":"15","author":"Biggin","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.matbio.2018.03.010_bb0650","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.c.31532","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"172","author":"Marom","year":"2016","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0655","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0660","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","article-title":"Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate","volume":"87","author":"Lindahl","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0670","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.matbio.2018.03.010_bb0675","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.matbio.2018.03.010_bb0680","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0685","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0690","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2040622315584114","article-title":"Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications","volume":"6","author":"Saita","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.matbio.2018.03.010_bb0695","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0700","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4248\/BR201301003","article-title":"Osteoclasts: new insights","volume":"1","author":"Feng","year":"2013","journal-title":"Bone Res"},{"key":"10.1016\/j.matbio.2018.03.010_bb0705","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10\u202fyears of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0710","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03008200903108472","article-title":"RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta","volume":"51","author":"Bargman","year":"2010","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0715","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.matbio.2018.03.010_bb0720","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.matbio.2018.03.010_bb0725","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0730","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1358\/dnp.2004.17.1.829022","article-title":"The role of cathepsin K in normal bone resorption","volume":"17","author":"Troen","year":"2004","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.matbio.2018.03.010_bb0735","doi-asserted-by":"crossref","first-page":"163","DOI":"10.11005\/jbm.2014.21.3.163","article-title":"Factors and mechanisms involved in the coupling from bone resorption to formation: how osteoclasts talk to osteoblasts","volume":"21","author":"Ikeda","year":"2014","journal-title":"J Bone Metab"},{"key":"10.1016\/j.matbio.2018.03.010_bb0740","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study","volume":"27","author":"Langdahl","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0745","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00198-016-3503-0","article-title":"Continuous treatment with odanacatib for up to 8\u202fyears in postmenopausal women with low bone mineral density: a phase 2 study","volume":"27","author":"Rizzoli","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0750","first-page":"669","article-title":"Merck & Co. drops osteoporosis drug odanacatib","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.matbio.2018.03.010_bb0755","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0760","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0765","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1759720X13510479","article-title":"Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases","volume":"6","author":"Lewiecki","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.matbio.2018.03.010_bb0770","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0775","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0780","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0785","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0790","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0795","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0800","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0805","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0810","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0815","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap(\u2212\/\u2212) mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0820","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(76)92216-9","article-title":"Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis","volume":"1","author":"Reeve","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.matbio.2018.03.010_bb0825","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"Br. Med. J."},{"key":"10.1016\/j.matbio.2018.03.010_bb0830","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/endo-110-2-506","article-title":"Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration","volume":"110","author":"Tam","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.matbio.2018.03.010_bb0835","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.matbio.2018.03.010_bb0840","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jbmr.5650110509","article-title":"Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model","volume":"11","author":"Lane","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0845","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0850","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2018.03.010_bb0855","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bone.2008.10.037","article-title":"Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts","volume":"44","author":"Jilka","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0860","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/00365513.2011.624631","article-title":"Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans","volume":"72","author":"Aslan","year":"2012","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.matbio.2018.03.010_bb0865","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.matbio.2018.03.010_bb0870","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.matbio.2018.03.010_bb0875","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2018.03.010_bb0880","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.matbio.2018.03.010_bb0885","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7150\/ijbs.2929","article-title":"TGF-beta and BMP signaling in osteoblast differentiation and bone formation","volume":"8","author":"Chen","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.matbio.2018.03.010_bb0890","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.matbio.2016.02.002","article-title":"Mechanobiology of TGFbeta signaling in the skeleton","volume":"52\u201354","author":"Rys","year":"2016","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.03.010_bb0895","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/sj.emboj.7600729","article-title":"Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3","volume":"24","author":"Kang","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.matbio.2018.03.010_bb0900","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1093\/emboj\/20.9.2254","article-title":"TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation","volume":"20","author":"Alliston","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.matbio.2018.03.010_bb0905","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1359\/jbmr.2001.16.10.1754","article-title":"The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis","volume":"16","author":"Borton","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2018.03.010_bb0910","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.1074\/jbc.M207205200","article-title":"Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis","volume":"277","author":"Karsdal","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2018.03.010_bb0915","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/bonekey.2014.13","article-title":"Combination therapy for osteoporosis: a reappraisal","volume":"3","author":"Cosman","year":"2014","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.matbio.2018.03.010_bb0920","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.matbio.2018.03.010_bb0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.09.021","article-title":"Effects of single or combination therapy of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in mice","volume":"106","author":"Kitaguchi","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.matbio.2018.03.010_bb0930","first-page":"670","article-title":"Phenotypic heterogeneity in osteogenesis imperfecta: the mildly affected mother of a proband with a lethal variant has the same mutation substituting cysteine for alpha 1-glycine 904 in a type I procollagen gene (COL1A1)","volume":"47","author":"Constantinou","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0935","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","article-title":"Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta","volume":"95","author":"Pereira","year":"1998","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.matbio.2018.03.010_bb0940","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0945","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2007-08-105809","article-title":"Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice","volume":"111","author":"Guillot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2018.03.010_bb0950","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2011-12-400085","article-title":"Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms","volume":"120","author":"Otsuru","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2018.03.010_bb0955","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2008-12-195859","article-title":"In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta","volume":"114","author":"Panaroni","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2018.03.010_bb0960","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","article-title":"Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta","volume":"79","author":"Le Blanc","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.matbio.2018.03.010_bb0965","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5966\/sctm.2013-0090","article-title":"Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience","volume":"3","author":"Gotherstrom","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.matbio.2018.03.010_bb0970","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.1088757","article-title":"Gene targeting in stem cells from individuals with osteogenesis imperfecta","volume":"303","author":"Chamberlain","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.matbio.2018.03.010_bb0975","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.7150\/ijms.5774","article-title":"Allele dependent silencing of collagen type I using small interfering RNAs targeting 3\u2032UTR Indels - a novel therapeutic approach in osteogenesis imperfecta","volume":"10","author":"Lindahl","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.matbio.2018.03.010_bb0980","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ejhg.2013.198","article-title":"Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta","volume":"22","author":"Rousseau","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb0985","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2018.03.010_bb0990","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molcel.2017.09.029","article-title":"Methods and applications of CRISPR-mediated base editing in eukaryotic genomes","volume":"68","author":"Hess","year":"2017","journal-title":"Mol. Cell"},{"issue":"7687","key":"10.1016\/j.matbio.2018.03.010_bb0995","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature25164","article-title":"Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents","volume":"553","author":"Gao","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2018.03.010_bb1000","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1093\/hmg\/ddv328","article-title":"Altered cytoskeletal organization characterized lethal but not surviving Brtl+\/\u2212 mice: insight on phenotypic variability in osteogenesis imperfecta","volume":"24","author":"Bianchi","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.matbio.2018.03.010_bb1005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jprot.2017.08.007","article-title":"Cytoskeleton and nuclear lamina affection in recessive osteogenesis imperfecta: a functional proteomics perspective","volume":"167","author":"Gagliardi","year":"2017","journal-title":"J. Proteome"}],"container-title":["Matrix Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X18300507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X18300507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:01:40Z","timestamp":1760554900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0945053X18300507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":201,"alternative-id":["S0945053X18300507"],"URL":"https:\/\/doi.org\/10.1016\/j.matbio.2018.03.010","relation":{},"ISSN":["0945-053X"],"issn-type":[{"value":"0945-053X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteogenesis imperfecta and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Matrix Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.matbio.2018.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}